Literature DB >> 22661083

Vasoactive intestinal peptide downregulates proinflammatory TLRs while upregulating anti-inflammatory TLRs in the infected cornea.

Xiaoyu Jiang1, Sharon A McClellan, Ronald P Barrett, Yunfan Zhang, Linda D Hazlett.   

Abstract

TLRs recognize microbial pathogens and trigger an immune response, but their regulation by neuropeptides, such as vasoactive intestinal peptide (VIP), during Pseudomonas aeruginosa corneal infection remains unexplored. Therefore, C57BL/6 (B6) mice were injected i.p. with VIP, and mRNA, protein, and immunostaining assays were performed. After VIP treatment, PCR array and real-time RT-PCR demonstrated that proinflammatory TLRs (conserved helix-loop-helix ubiquitous kinase, IRAK1, TLR1, TLR4, TLR6, TLR8, TLR9, and TNFR-associated factor 6) were downregulated, whereas anti-inflammatory TLRs (single Ig IL-1-related receptor [SIGIRR] and ST2) were upregulated. ELISA showed that VIP modestly downregulated phosphorylated inhibitor of NF-κB kinase subunit α but upregulated ST2 ~2-fold. SIGIRR was also upregulated, whereas TLR4 immunostaining was reduced in cornea; all confirmed the mRNA data. To determine whether VIP effects were cAMP dependent, mice were injected with small interfering RNA for type 7 adenylate cyclase (AC7), with or without VIP treatment. After silencing AC7, changes in mRNA levels of TLR1, TNFR-associated factor 6, and ST2 were seen and unchanged with addition of VIP, indicating that their regulation was cAMP dependent. In contrast, changes were seen in mRNA levels of conserved helix-loop-helix ubiquitous kinase, IRAK1, 2, TLR4, 9 and SIGIRR following AC7 silencing alone; these were modified by VIP addition, indicating their cAMP independence. In vitro studies assessed the effects of VIP on TLR regulation in macrophages and Langerhans cells. VIP downregulated mRNA expression of proinflammatory TLRs while upregulating anti-inflammatory TLRs in both cell types. Collectively, the data provide evidence that VIP downregulates proinflammatory TLRs and upregulates anti-inflammatory TLRs and that this regulation is both cAMP dependent and independent and involves immune cell types found in the infected cornea.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22661083      PMCID: PMC3415258          DOI: 10.4049/jimmunol.1200365

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  47 in total

1.  SIGIRR/TIR-8 is an inhibitor of Toll-like receptor signaling in primary human cells and regulates inflammation in models of rheumatoid arthritis.

Authors:  Stefan K Drexler; Philip Kong; Julia Inglis; Richard O Williams; Cecilia Garlanda; Alberto Mantovani; Amir S Yazdi; Fionula Brennan; Marc Feldmann; Brian M J Foxwell
Journal:  Arthritis Rheum       Date:  2010-08

2.  Distinct roles of adenylyl cyclase VII in regulating the immune responses in mice.

Authors:  Biyan Duan; Richard Davis; Eva L Sadat; Julie Collins; Paul C Sternweis; Dorothy Yuan; Lily I Jiang
Journal:  J Immunol       Date:  2010-05-26       Impact factor: 5.422

Review 3.  The IKK complex, a central regulator of NF-kappaB activation.

Authors:  Alain Israël
Journal:  Cold Spring Harb Perspect Biol       Date:  2010-03       Impact factor: 10.005

4.  TLR4 and TLR5 on corneal macrophages regulate Pseudomonas aeruginosa keratitis by signaling through MyD88-dependent and -independent pathways.

Authors:  Yan Sun; Mausita Karmakar; Sanhita Roy; Raniyah T Ramadan; Susan R Williams; Scott Howell; Carey L Shive; Yiping Han; Charles M Stopford; Arne Rietsch; Eric Pearlman
Journal:  J Immunol       Date:  2010-09-08       Impact factor: 5.422

5.  Enhanced expression of single immunoglobulin IL-1 receptor-related molecule ameliorates LPS-induced acute lung injury in mice.

Authors:  XuXin Chen; YunFeng Zhao; XueLing Wu; GuiSheng Qian
Journal:  Shock       Date:  2011-02       Impact factor: 3.454

6.  VIP reverses the expression profiling of TLR4-stimulated signaling pathway in rheumatoid arthritis synovial fibroblasts.

Authors:  Alicia Arranz; Irene Gutiérrez-Cañas; Mar Carrión; Yasmina Juarranz; José Luis Pablos; Carmen Martínez; Rosa P Gomariz
Journal:  Mol Immunol       Date:  2008-05-02       Impact factor: 4.407

Review 7.  Immunomodulation of innate immune responses by vasoactive intestinal peptide (VIP): its therapeutic potential in inflammatory disease.

Authors:  S G R Smalley; P A Barrow; N Foster
Journal:  Clin Exp Immunol       Date:  2009-08       Impact factor: 4.330

8.  Toll-like receptors involved in the pathogenesis of experimental Candida albicans keratitis.

Authors:  Xiaoyong Yuan; Kirk R Wilhelmus
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-11-20       Impact factor: 4.799

9.  Vasoactive intestinal peptide inhibits toll-like receptor 3-induced nitric oxide production in Schwann cells and subsequent sensory neuronal cell death in vitro.

Authors:  Hyunkyoung Lee; Kyungpyo Park; Joong Soo Kim; Sung Joong Lee
Journal:  J Neurosci Res       Date:  2009-01       Impact factor: 4.164

Review 10.  Peptides targeting Toll-like receptor signalling pathways for novel immune therapeutics.

Authors:  R P Gomariz; I Gutiérrez-Cañas; A Arranz; M Carrión; Y Juarranz; J Leceta; C Martínez
Journal:  Curr Pharm Des       Date:  2010       Impact factor: 3.116

View more
  29 in total

1.  Efficacy of VIP as Treatment for Bacteria-Induced Keratitis Against Multiple Pseudomonas aeruginosa Strains.

Authors:  Thomas W Carion; Cody R McWhirter; Daiyajot K Grewal; Elizabeth A Berger
Journal:  Invest Ophthalmol Vis Sci       Date:  2015-10       Impact factor: 4.799

2.  High-mobility group box 1: a novel target for treatment of Pseudomonas aeruginosa keratitis.

Authors:  Sharon McClellan; Xiaoyu Jiang; Ronald Barrett; Linda D Hazlett
Journal:  J Immunol       Date:  2015-01-14       Impact factor: 5.422

Review 3.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

4.  Antibiotic-Induced Depletion of Murine Microbiota Induces Mild Inflammation and Changes in Toll-Like Receptor Patterns and Intestinal Motility.

Authors:  Laura Grasa; Leticia Abecia; Raquel Forcén; Marta Castro; José Antonio García de Jalón; Eva Latorre; Ana Isabel Alcalde; María Divina Murillo
Journal:  Microb Ecol       Date:  2015-04-21       Impact factor: 4.552

5.  Role of VIP and Sonic Hedgehog Signaling Pathways in Mediating Epithelial Wound Healing, Sensory Nerve Regeneration, and Their Defects in Diabetic Corneas.

Authors:  Yangyang Zhang; Nan Gao; Lin Wu; Patrick S Y Lee; Rao Me; Chenyang Dai; Lixin Xie; Fu-Shin X Yu
Journal:  Diabetes       Date:  2020-04-28       Impact factor: 9.461

Review 6.  Review of clinical and basic approaches of fungal keratitis.

Authors:  Jie Wu; Wen-Song Zhang; Jing Zhao; Hong-Yan Zhou
Journal:  Int J Ophthalmol       Date:  2016-11-18       Impact factor: 1.779

7.  The role of VIP in cornea.

Authors:  Xiaoyu Jiang; Sharon A McClellan; Ronald P Barrett; Yunfan Zhang; Megan E Foldenauer; Linda D Hazlett
Journal:  Invest Ophthalmol Vis Sci       Date:  2012-11-07       Impact factor: 4.799

8.  Secretory IgA in complex with Lactobacillus rhamnosus potentiates mucosal dendritic cell-mediated Treg cell differentiation via TLR regulatory proteins, RALDH2 and secretion of IL-10 and TGF-β.

Authors:  Josip Mikulic; Stéphanie Longet; Laurent Favre; Jalil Benyacoub; Blaise Corthesy
Journal:  Cell Mol Immunol       Date:  2016-03-14       Impact factor: 11.530

9.  Effect of vasoactive intestinal peptide on the wound healing of alkali-burned corneas.

Authors:  Nese Tuncel; Nilgun Yildirim; Firdevs Gurer; Hikmet Basmak; Kubilay Uzuner; Varol Sahinturk; Huseyin Gursoy
Journal:  Int J Ophthalmol       Date:  2016-02-18       Impact factor: 1.779

10.  Role of vasoactive intestinal peptide in Aspergillus fumigatus-infected cornea.

Authors:  Cui Li; Yuan-Yuan Liu; Gui-Qiu Zhao; Jing Lin; Cheng-Ye Che; Nan Jiang; Na Li; Jie Zhang; Kun He; Xu-Dong Peng
Journal:  Int J Ophthalmol       Date:  2018-02-18       Impact factor: 1.779

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.